Idoxuridine

Idoxuridine is a pyrimidine analog. Research in antiviral chemotherapy began in the early 1950s, when the search for cancer treatments generated several new compounds capable of inhibiting viral DNA synthesis. Idoxuridine was the first antiviral agent to be approved. Idoxuridine is used topically but because of the lack of selectivity Idoxuridine is too toxic for systemic administration. Used topically for treating herpes simplex infections of the skin & internal genitalia.

Idoxuridine is primarily indicated in conditions like Cutaneous herpes simplex, Cutaneous herpes zoster, Herpes simplex keratitis, Soft tissue sarcoma.

Idoxuridine is contraindicated in conditions like Dermatographia, Hypersensitivity.

The severe or irreversible adverse effects of Idoxuridine, which give rise to further complications include Alopecia, Thrombocytopenia, Stomatitis, Leucopenia, Punctate keratitis, Epithelial degeneration. Idoxuridine produces potentially life-threatening effects which include Bone marrow, potential carcinogen & teratogen, Depression, Liver damage. which are responsible for the discontinuation of Idoxuridine therapy. The symptomatic adverse reactions produced by Idoxuridine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Pruritus, Pain, Contact dermatitis, Lacrimation, Photophobia, Follicular conjunctivitis, Heaviness of the lid, Maceration of the skin, Corneal clouding, Stinging, Stippling.

Idoxuridine should be used with caution in condition where there is deep ulceration of the cornea. Prolonged topical use should be avoided. Avoid use during pregnancy. Corticosteroids should be applied with caution in patients also receiving idoxuridine, as they may accelerate the spread of viral infection. Boric acid preparation should not be applied to the eye in patients receiving eye preparation of idoxuridine, because irritation may occur.

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

0.005 mg (0.005 (0.005)) As recommended. Ophthalmic — Initially per hour for 12 hours 10 % (10 (10)) As recommended. Opthalimc Ointment — As required 5 % (5 (5)) As recommended. Topical — As Required

( ) — Not recommended in this age group

( ) — Not recommended in this age group

No data regarding the interactions of Idoxuridine was found.

Eye Drops, Eye Oint Store in a well closed container. Refrigeration is recommended. Protect from Sunlight. Soln Store in a well closed container, Below 25°C. Protect from Sunlight.